drugset / Trial / NCT01188317

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

NCT01188317 ↗

Phase 1 Completed 44 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, double-blind, placebo-controlled, parallel group study will investigate the safety and tolerability, and the effect of aleglitazar in combination with ibuprofen on renal function, renin-angiotensin system and pharmacokinetics in healthy volunteers. Volunteers will be randomized to receive daily doses of aleglitazar or placebo in combination with ibuprofen. The anticipated time on study drug is 5 weeks.

Timeline

Start
2010-06
Primary completion
—
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibuprofen Small molecule — —
Subject aleglitazar Small molecule 150 ug —

Indications

No indication recorded.